On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026. The firm shed light on the biopharma segment, which is entering 2026 with renewed momentum and a compelling case for investors paying attention. After a slower stretch, mergers and acquisitions are picking back up and for good [...]
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
